Highline Wealth Partners’s abrdn Life Sciences Investors HQL Stock Holding History
Bought
Maintained
Sold
Other funds holding HQL
DI
Highline Wealth Partners's HQL Position: Q3 2026 in Review
Highline Wealth Partners opened a new position in abrdn Life Sciences Investors (HQL) in Q3 2026: 135 shares worth $2.52K. The stake represents ﹤0.01% of the portfolio and ranks #1182 among its holdings. This is a return to the name: Highline Wealth Partners previously reported a position in HQL as recently as Q1 2026.
Highline Wealth Partners first reported a position in HQL in Q3 2025 and has held it in 4 quarters since. The position peaked at $15.5K in Q3 2025. 5 funds tracked by Wall St. Rank hold HQL as of Q3 2026.
- Highline Wealth Partners held 135 shares of abrdn Life Sciences Investors worth $2.52K as of Q3 2026.
- abrdn Life Sciences Investors was a new Highline Wealth Partners position in Q3 2026.
- abrdn Life Sciences Investors made up ﹤0.01% of Highline Wealth Partners's portfolio in Q3 2026, its #1182 holding.
- Highline Wealth Partners first reported a position in abrdn Life Sciences Investors in Q3 2025 and has held it in 4 quarters since.
- Highline Wealth Partners's abrdn Life Sciences Investors position peaked at $15.5K in Q3 2025.
- 5 funds tracked by Wall St. Rank held abrdn Life Sciences Investors as of Q3 2026.
Based on Highline Wealth Partners's 13F filing for Q3 2026, filed 19 Oct 2026.